melagatran has been researched along with glycine in 111 studies
Studies (melagatran) | Trials (melagatran) | Recent Studies (post-2010) (melagatran) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
---|---|---|---|---|---|
185 | 32 | 19 | 35,163 | 756 | 8,415 |
Protein | Taxonomy | melagatran (IC50) | glycine (IC50) |
---|---|---|---|
Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 7 (6.31) | 18.2507 |
2000's | 104 (93.69) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Deinum, J; Elg, M; Gustafsson, D | 1 |
Carlsson, S; Eriksson, BI; Halvarsson, M; Mattsson, C; Risberg, B | 1 |
Antonsson, T; Bylund, R; Deinum, J; Elg, M; Eriksson, U; Gustafsson, D; Gyzander, E; Karlsson, O; Mattsson, C; Nilsson, A; Nilsson, I; Pehrsson, S; Sörensen, H | 1 |
Chen, L; Gustafsson, D; Mattsson, C; Mehta, JL; Nichols, WW; Saldeen, TG | 1 |
Eriksson, M; Larsson, A; Mattsson, C; Saldeen, T | 2 |
Deinum, J; Nilsson, T; Sjöling-Ericksson, A | 1 |
Eriksson, H; Eriksson, UG; Frison, L; Hägg, A; Hansson, PO; Held, P; Holmström, M; Jonsson, T; Lapidus, L; Leijd, B; Säfwenberg, U; Stockelberg, D; Taghavi, A; Thorsén, M | 1 |
Basu, S; Eriksson, M; Eriksson, O; Kiiski, R; Larsson, A; Mattsson, C; Nordgren, A | 1 |
Carlsson, S; Elg, M; Gustafsson, D | 2 |
Abrahamsson, A; Antonsson, T; Bredberg, U; Bylund, R; Carlsson, S; Elg, M; Eriksson, U; Gustafsson, D; Gyzander, E; Hoffmann, K; Någård, S; Nyström, J; Sörensen, H; Ungell, A | 1 |
Heinzl, S | 1 |
Hauptmann, J; Steinmetzer, T; Sturzebecher, J | 1 |
Elg, M; Gustafsson, D; Mikulski, A | 1 |
Fleischer, K; Gulba, DC; Lankes, W | 1 |
Bode, C; Darius, H; Diehm, C; Encke, A; Gulba, DC; Haas, S; Hacke, W; Puhl, W; Quante, M; Riess, H; Scharf, R; Schellong, S; Schrör, T; Schulte, KL; Tebbe, U; Van Aken, H | 1 |
Lindahl, TL; Mattsson, C; Menschiek-Lundin, A; Wåhlander, K | 1 |
Abrahamsson, P; Ahnoff, M; Larsson, M; Lindmark, B; Logren, U; Persson, BA; Svennberg, H | 1 |
Arfwidsson, AC; Bylock, A; Eriksson, BI; Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Kälebo, P | 1 |
Fiessinger, JN | 1 |
Marder, VJ | 1 |
Abrahamsson, T; Björkman, JA; Hendriks, D; Leurs, J; Mattsson, C; Nerme, V; Scharpé, S; Schatteman, K | 1 |
Andersson, C; Bylock, A; Eriksson, BI; Frison, L; Gustafsson, D; Larson, G; Lindahl, TL; Wåhlander, K | 1 |
Ekdahl, KN; Elgue, G; Korsgren, O; Larsson, R; Nilsson, B; Ozmen, L | 1 |
Ahnfelt, L; Arfwidsson, AC; Björkström, S; Elvander, CS; Eriksson, BI; Eriksson, UG; Folestad, A; Frison, L; Kälebo, P; Ogren, M; Sjöstedt, A | 1 |
Lassila, R | 1 |
Fenyvesi, T; Harenberg, J; Jörg, I | 1 |
Fenyvesi, T; Harenberg, J; Jörg, I; Piazolo, L; Zokai, K | 1 |
Fenyvesi, T; Harenberg, J; Joerg, I | 1 |
Eriksson, H; Eriksson, UG; Lapidus, L; Larson, G; Olsson, CG; Thuresson, A; Wåhlander, K | 1 |
Carlsson, S; Elg, M; Mattsson, C | 1 |
Bergqvist, D; Bylock, A; Dahl, OE; Eriksson, BI; Eriksson, UG; Frison, L; Gustafsson, D; Kälebo, P; Lindbratt, S; Welin, L | 1 |
Abrahamsson, A; Ahnoff, M; Fakt, C; Larsson, M; Logren, U; Ohrman, I; Persson, BA | 1 |
Agnelli, G; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Frison, L; Mouret, P; Nylander, I; Ogren, M; Rosencher, N | 1 |
Frebelius, S; Jansson, K; Linder, R; Swedenborg, J | 1 |
Mattsson, C; Nylander, S | 1 |
Haas, S | 2 |
Eriksson, UG; Fager, G; Frison, L; Gustafsson, D; Johansson, LC; Logren, U | 1 |
Clement, B; Lopian, K | 1 |
Björnheden, T; Carlsson, S; Grip, L; Mattsson, C; Scherstén, F; Wahlund, G | 1 |
Hamaad, A; Lip, GY; Tayebjee, MH | 1 |
Bodendiek, I; Bruhn, HD; Lentz, S; Seeger, M | 1 |
Andersson, M; Eriksson, UG; Fager, G; Gustafsson, D; Johansson, LC | 1 |
Eriksson, UG; Homolka, R; Peters, GR; Sarich, TC; Svensson, M; Teng, R; Wollbratt, M | 1 |
Ahnoff, M; Bredberg, U; Eriksson, UG; Frison, L; Gislén, K; Gustafsson, D; Johansson, LC | 1 |
Elg, M; Gustafsson, D | 1 |
Eriksson, BI | 1 |
Eriksson, BI; Eriksson, UG; Frison, L; Gisleskog, PO; Gustafsson, D; Hamrén, B; Karlsson, MO; Mandema, JW; Wählby, U | 1 |
Cullberg, M; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L | 1 |
Attman, PO; Eriksson, UG; Fager, G; Frison, L; Johansson, S; Mulec, H; Samuelsson, O | 1 |
Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Frison, L; Wåhlander, K | 1 |
Andersson, TB; Bredberg, E; Eriksson, UG; Eriksson-Lepkowska, M; Frison, L; Johansson, S; Larsson, M; Thuresson, A | 1 |
Boström, SL; Hansson, GF; Kjaer, M; Sarich, TC | 1 |
Adams, TE; Everse, SJ; Mann, KG | 1 |
Carlsson, S; Johnston, M; Klement, P; Liao, P; Rak, J; Stafford, A; Vlasin, M; Weitz, JI | 1 |
Eriksson, UG; Grind, M; Svensson, M; Wåhlander, K; Wollbratt, M; Wolzt, M | 1 |
Börjesson, I; Carlsson, S; Elg, M | 1 |
Gustafsson, D | 1 |
Braunwald, E; Giugliano, RP | 1 |
Choi, NH; Kim, BH; Ok, JH; Park, SY | 1 |
Frebelius, S; Grip, L; Linder, R; Swedenborg, J | 1 |
Elalamy, I; Lebrazi, J; Samama, MM | 1 |
Eriksson, UG; Johansson, S; Larson, G; Larsson, M; Ohlsson, L; Wåhlander, K | 1 |
Drouet, L | 1 |
Fenyvesi, T; Harenberg, J; Jörg, I; Weiss, C | 2 |
Eichinger, S; Kyrle, PA; Weltermann, A | 1 |
Agnelli, G; Andersson, M; Cohen, AT; Dahl, OE; Eriksson, BI; Eskilson, C; Freij, A; Kälebo, P; Lassen, MR; Mouret, P; Panfilov, S; Rosencher, N | 1 |
Kleinschmidt, S; Pindur, G; Ziegeler, S | 1 |
Bijsterveld, NR; Keller, TT; Levi, M | 1 |
Evans, HC; Faulds, D; Perry, CM | 1 |
Falk, E; Hansson, GK; Hemdahl, AL; Thorén, P | 1 |
Cvirn, G; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W; Rehak, T; Roschitz, B | 1 |
Al-Mousa, EN; Salam, AM | 1 |
Boström, SL; Dagnelid, E; Hansson, GF; Ulvinge, JC | 1 |
Eikelboom, JW; Hankey, GJ | 1 |
Boström, SL; Elg, M; Eriksson, UG; Eriksson-Lepkowska, M; Levi, M; Sarich, TC; Svensson, M; Wåhlander, K; Weitz, JI; Wolzt, M | 1 |
Weitz, J | 1 |
Bauersachs, RM | 1 |
Samama, MM | 1 |
Bauersachs, R; Brehme, S; Caspary, L; Creutzig, A; Harenberg, J; Hoffmann, U; Landgraf, H; Schellong, S | 1 |
Agnelli, G; Andersson, M; Cohen, A; Dahl, O; Eriksson, BI; Mouret, P; Panfilov, S; Rosencher, N | 1 |
Dorani, H; Eriksson, UG; Kalies, I; Ohlsson, L; Sarich, TC; Schützer, KM; Wall, U | 1 |
Eriksson, UG; Kessler, E; Sarich, TC; Schützer, KM; Wall, U; Wollbratt, M | 1 |
Brighton, TA | 1 |
Cimminiello, C; Planès, A; Samama, MM | 1 |
Baier, K; Cvirn, G; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W | 2 |
Cvirn, G; Gallistl, S; Koestenberger, M; Muntean, W | 1 |
Andersen, JC | 1 |
Boda, Z | 1 |
Petersen, P | 1 |
Eriksson, UG; Hellgren, M; Johansson, S; Wåhlander, K | 1 |
Auboyer, C; Laporte, S; Mismetti, P; Molliex, S; Zufferey, P | 1 |
Carlsson, S; Elg, M | 1 |
Furugohri, T; Honda, Y; Isobe, K; Matsumoto, C; Muramatsu, S; Shiozaki, Y; Sugiyama, N | 1 |
Attman, PO; Eriksson, UG; Eriksson-Lepkowska, M; Fager, G; Ottosson, P; Samuelsson, O | 1 |
Nielsen, JD | 1 |
Flanigan, MJ | 1 |
Cvirn, G; Fritsch, P; Gallistl, S; Koestenberger, M; Leschnik, B; Muntean, W | 1 |
Hering, D; Horstkotte, D; Piper, C | 1 |
Eriksson, UG; Sarich, TS; Wolzt, M | 2 |
Cvirn, G; Gallistl, S; Koestenberger, M; Kutschera, J; Muntean, W | 1 |
Bylock, A; Christersson, C; Oldgren, J; Siegbahn, A; Wallentin, L | 1 |
Meyer Samama, M | 1 |
Craven, S; Dewar, L; Greinacher, A; Ofosu, FA; Sheppard, JA; Warkentin, TE | 1 |
31 review(s) available for melagatran and glycine
Article | Year |
---|---|
Effects of melagatran, a novel direct thrombin inhibitor, during experimental septic shock.
Topics: Animals; Azetidines; Benzylamines; Glycine; Humans; Shock, Septic; Thrombin | 2000 |
Advances in the development of thrombin inhibitors.
Topics: Arginine; Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Hirudin Therapy; Hirudins; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2001 |
[Direct thrombin antagonists].
Topics: Acute Disease; Angina, Unstable; Angioplasty, Balloon, Coronary; Animals; Anticoagulants; Antithrombins; Arginine; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Hirudin Therapy; Hirudins; Humans; Myocardial Infarction; Peptide Fragments; Pipecolic Acids; Platelet Aggregation Inhibitors; Rabbits; Recombinant Proteins; Sulfonamides; Syndrome; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2001 |
Anticoagulation: the present and future.
Topics: Administration, Oral; Amino Acid Chloromethyl Ketones; Anticoagulants; Arginine; Azetidines; Benzylamines; Binding Sites; Biological Availability; Blood Coagulation; Comorbidity; Coumarins; Drug Design; Embolism; Female; Forecasting; Glycine; Guanidines; Heart Diseases; Hemorrhage; Heparin; Heparin, Low-Molecular-Weight; Hirudin Therapy; Humans; Neoplasms; Pipecolic Acids; Pregnancy; Pregnancy Complications, Hematologic; Prodrugs; Safety; Serine; Stroke; Sulfonamides; Thrombin; Thrombophilia; Thrombosis | 2001 |
[Treatment of deep vein thrombosis. Current and future questions].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Hemorrhage; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Recurrence; Risk Factors; Venous Thrombosis | 2001 |
[Thrombosis in spite of warfarin--what should be done?].
Topics: Anticoagulants; Antiphospholipid Syndrome; Azetidines; Benzylamines; Blood Coagulation; Glycine; Heparin, Low-Molecular-Weight; Humans; International Normalized Ratio; Neoplasms; Recurrence; Thrombin; Thrombosis; Treatment Failure; Warfarin | 2001 |
The METHRO trials.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Prodrugs; Thrombin; Venous Thrombosis | 2003 |
The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review.
Topics: Azetidines; Benzylamines; Glycine; Hemostasis; Humans; Pharmacokinetics; Prodrugs; Thrombin; Thrombosis | 2003 |
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome | 2003 |
Medical indications and considerations for future clinical decision making.
Topics: Azetidines; Benzylamines; Cardiovascular Diseases; Clinical Protocols; Clinical Trials as Topic; Glycine; Humans; Thromboembolism | 2003 |
Oral direct thrombin inhibitors in clinical development.
Topics: Anticoagulants; Azetidines; Benzimidazoles; Benzylamines; Dabigatran; Glycine; Hemostasis; Humans; Prodrugs; Pyridines; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
[Treatment and prevention of venous thromboembolic events: present and future antithrombotic agents].
Topics: Administration, Oral; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Thrombosis; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Hirudin Therapy; Humans; Orthopedics; Polysaccharides; Prodrugs; Prothrombin; Research; Thrombin; Thromboembolism; Time Factors; Venous Thrombosis | 2003 |
Novel anticoagulants for the prevention and treatment of venous thromboembolism.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation Factors; Drugs, Investigational; Fondaparinux; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Pulmonary Embolism; Research; Thrombin; Venous Thrombosis; Vitamin K | 2003 |
[Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects].
Topics: Anesthesia; Animals; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Half-Life; Humans | 2003 |
Recombinant factor VIIa as an antidote for anticoagulant treatment.
Topics: Anticoagulants; Azetidines; Benzylamines; Factor VII; Factor VIIa; Glycine; Helminth Proteins; Hemorrhage; Humans; Platelet Aggregation Inhibitors; Recombinant Proteins | 2004 |
Ximelagatran/Melagatran: a review of its use in the prevention of venous thromboembolism in orthopaedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Drug Interactions; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Randomized Controlled Trials as Topic; Thrombin; Thromboembolism; Venous Thrombosis; Warfarin | 2004 |
The therapeutic potential of ximelagatran to become the anticoagulant of choice in medicine: a review of recently completed clinical trials.
Topics: Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Clinical Trials as Topic; Coronary Artery Disease; Drug Therapy, Combination; Glycine; Humans; Prodrugs; Stroke; Thrombin; Thromboembolism; Venous Thrombosis | 2004 |
Orally active direct thrombin inhibitors.
Topics: Administration, Oral; Anticoagulants; Atrial Fibrillation; Azetidines; Benzylamines; Blood Coagulation; Drug Monitoring; Glycine; Humans; International Normalized Ratio; Postoperative Complications; Prodrugs; Stroke; Thrombin; Thrombosis; Venous Thrombosis; Vitamin K | 2003 |
[Low molecular weight heparin, fondaparinux and melagatran: new data and clinical studies].
Topics: Angina, Unstable; Animals; Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin, Low-Molecular-Weight; Humans; Polysaccharides; Thrombosis | 2004 |
[Prevention and treatment of deep vein thrombosis with ximelagatran].
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Fondaparinux; Glycine; Heparin; Hirudin Therapy; Humans; Pipecolic Acids; Polysaccharides; Prodrugs; Sulfonamides; Thrombin; Venous Thrombosis | 2004 |
The direct thrombin inhibitor melagatran/ximelagatran.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Glycine; Humans; Myocardial Infarction; Secondary Prevention; Stroke; Thrombin; Treatment Outcome; Venous Thrombosis | 2004 |
Advances in anticoagulation therapy: the role of selective inhibitors of factor Xa and thrombin in thromboprophylaxis after major orthopedic surgery.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Factor Xa Inhibitors; Fondaparinux; Glycine; Heparin; Heparin, Low-Molecular-Weight; Humans; Models, Biological; Orthopedics; Polysaccharides; Postoperative Complications; Thromboembolism; Thrombolytic Therapy | 2004 |
[New anticoagulants in clinical practice].
Topics: Anticoagulants; Azetidines; Benzylamines; Fondaparinux; Glycine; Humans; Polysaccharides; Protein C; Pulmonary Embolism; Recombinant Proteins; Venous Thrombosis | 2004 |
Ximelagatran--a promising new drug in thromboembolic disorders.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Randomized Controlled Trials as Topic; Stroke; Thrombin; Thromboembolism; Venous Thrombosis | 2005 |
Ximelagatran and melagatran vs. low-molecular-weight heparin in major orthopedic surgery: relationship between efficacy and safety and timing of initial administration.
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Humans; Meta-Analysis as Topic; Orthopedics; Random Allocation; Regression Analysis; Risk; Risk Factors; Thrombin; Thromboembolism | 2005 |
[Thromboprophylaxis in hip and knee arthroplasty. Are the new anticoagulants better than those previously used?].
Topics: Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Clinical Trials, Phase III as Topic; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Polysaccharides; Postoperative Complications; Pulmonary Embolism; Thromboembolism; Venous Thrombosis | 2005 |
Melagatran anticoagulation during haemodialysis--'Primum non nocere'.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Heparin; Humans; Renal Dialysis; Safety | 2005 |
Drug insight: an overview of current anticoagulation therapy after heart valve replacement.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Heart Valve Prosthesis; Heparin, Low-Molecular-Weight; Humans; Thromboembolism; Vitamin K | 2005 |
Pharmacokinetics and pharmacodynamics of ximelagatran.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Glycine; Humans; Thrombin | 2005 |
Low potential for interactions between melagatran/ximelagatran and other drugs, food, or alcohol.
Topics: Anticoagulants; Azetidines; Benzylamines; Cytochrome P-450 Enzyme System; Drug Interactions; Ethanol; Food; Glycine; Humans | 2005 |
[The new antithrombotic agents].
Topics: Administration, Oral; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Hirudins; Humans; Injections, Subcutaneous; Platelet Aggregation Inhibitors; Polysaccharides; Prodrugs; Randomized Controlled Trials as Topic; Stents; Thrombosis; Ticlopidine; Time Factors; Venous Thrombosis | 2005 |
27 trial(s) available for melagatran and glycine
Article | Year |
---|---|
Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Female; Glycine; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombin; Thrombophlebitis; Treatment Outcome | 1999 |
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in
Topics: Administration, Oral; Adolescent; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Female; Glycine; Humans; Incidence; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Postoperative Complications; Prodrugs; Safety; Sweden; Thrombin; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2002 |
Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery.
Topics: Activated Protein C Resistance; Adolescent; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; DNA Mutational Analysis; Double-Blind Method; Europe; Factor V; Female; Genetic Predisposition to Disease; Genotype; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Promoter Regions, Genetic; Prospective Studies; Prothrombin; Pulmonary Embolism; Risk Factors; Thrombophilia; Venous Thrombosis | 2002 |
Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement: results from Phase II studies.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cyclodextrins; Female; Fibrinolytic Agents; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Partial Thromboplastin Time; Phlebography; Thromboembolism; Venous Thrombosis | 2002 |
Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis.
Topics: Administration, Oral; Adult; Aged; Azetidines; Benzylamines; Female; Fibrinolytic Agents; Glycine; Humans; Male; Middle Aged; Partial Thromboplastin Time; Pharmacokinetics; Prodrugs; Pulmonary Embolism; Thrombin; Treatment Outcome; Venous Thrombosis | 2002 |
Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial.
Topics: Adult; Aged; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Glycine; Humans; Male; Middle Aged; Postoperative Complications; Prodrugs; Thromboembolism | 2002 |
Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Cause of Death; Double-Blind Method; Drug Administration Schedule; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Injections, Subcutaneous; Male; Middle Aged; Postoperative Complications; Prodrugs; Prospective Studies; Pulmonary Embolism; Safety; Thrombin; Treatment Outcome; Venous Thrombosis | 2003 |
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Topics: Administration, Oral; Adult; Age Factors; Aged; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Cross-Over Studies; Female; Fibrinolytic Agents; Food-Drug Interactions; Glycine; Humans; Infusions, Intravenous; Injections, Subcutaneous; Male; Metabolic Clearance Rate; Middle Aged; Prodrugs; Thrombin | 2003 |
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Azetidines; Benzylamines; Black People; Glycine; Humans; Inactivation, Metabolic; Male; Prodrugs; Racial Groups; Thrombin; White People | 2003 |
No influence of obesity on the pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran.
Topics: Administration, Oral; Adult; Area Under Curve; Azetidines; Benzylamines; Female; Glycine; Half-Life; Humans; Inactivation, Metabolic; Male; Obesity; Thrombin | 2003 |
Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects.
Topics: Administration, Oral; Adult; Analysis of Variance; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Food-Drug Interactions; Glycine; Half-Life; Humans; Male; Metabolic Clearance Rate; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin | 2003 |
Clinical experience of melagatran/ximelagatran in major orthopaedic surgery.
Topics: Azetidines; Benzylamines; Clinical Trials as Topic; Glycine; Humans; Orthopedic Procedures; Thromboembolism; Thrombosis; Treatment Outcome | 2003 |
Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis.
Topics: Administration, Cutaneous; Administration, Oral; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Biological Availability; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Glycine; Humans; Metabolic Clearance Rate; Partial Thromboplastin Time; Postoperative Complications; Sweden; Thromboembolism; Venous Thrombosis; Whole Blood Coagulation Time | 2003 |
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Topics: Administration, Oral; Adult; Aspirin; Azetidines; Benzylamines; Blood Coagulation; Cross-Over Studies; Double-Blind Method; Drug Interactions; Glycine; Humans; Infusions, Intravenous; Male; Partial Thromboplastin Time; Platelet Aggregation Inhibitors; Prodrugs; Thrombin; Whole Blood Coagulation Time | 2003 |
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Topics: Administration, Oral; Adult; Aged; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Glycine; Half-Life; Humans; Injections, Subcutaneous; International Normalized Ratio; Kidney Failure, Chronic; Male; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Thrombin; Time Factors | 2003 |
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Glycine; Half-Life; Humans; Liver Diseases; Metabolic Clearance Rate; Middle Aged; Partial Thromboplastin Time; Prodrugs; Prothrombin Time; Thrombin | 2003 |
Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions.
Topics: Administration, Oral; Adult; Aged; Amidines; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Diazepam; Diclofenac; Drug Interactions; Glycine; Humans; In Vitro Techniques; Infusions, Intravenous; Microsomes, Liver; Middle Aged; Nifedipine; Nordazepam; Prodrugs; Thrombin | 2003 |
Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects.
Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Factor Xa Inhibitors; Glycine; Humans; Inhibitory Concentration 50; Injections, Subcutaneous; Male; Reference Values; Thrombin; Time Factors; Veins | 2003 |
Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects.
Topics: Administration, Oral; Adult; Aged; Aging; Area Under Curve; Atrial Fibrillation; Azetidines; Benzylamines; Female; Glycine; Humans; Infusions, Intravenous; Male; Middle Aged; Thrombin | 2003 |
Pharmacokinetics and anticoagulant effect of the direct thrombin inhibitor melagatran following subcutaneous administration to healthy young men.
Topics: Adult; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Biological Availability; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Glycine; Half-Life; Hemorrhage; Humans; Injections, Subcutaneous; Male; Pharmacokinetics; Thrombin | 2003 |
The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study.
Topics: Adult; Aged; Aged, 80 and over; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Double-Blind Method; Enoxaparin; Female; Glycine; Hemorrhage; Humans; Male; Middle Aged; Preoperative Care; Therapeutic Equivalency; Thrombin; Thromboembolism; Venous Thrombosis | 2003 |
Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
Topics: Adult; Azetidines; Benzylamines; Biomarkers; Blood Coagulation Tests; Dose-Response Relationship, Drug; Drug Interactions; Factor VII; Factor VIIa; Glycine; Humans; Male; Platelet Activation; Recombinant Proteins; Single-Blind Method; Thrombosis; Time Factors | 2004 |
Significantly lower need for blood transfusions associated with post-operatively initiated subcutaneous melagatran/oral ximelagatran compared with enoxaparin.
Topics: Administration, Oral; Anticoagulants; Arthroplasty, Replacement, Hip; Arthroplasty, Replacement, Knee; Azetidines; Benzylamines; Blood Transfusion; Drug Therapy, Combination; Enoxaparin; Glycine; Humans; Logistic Models; Odds Ratio; Time Factors | 2004 |
No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran.
Topics: Administration, Oral; Adult; Anticholesteremic Agents; Anticoagulants; Area Under Curve; Atorvastatin; Azetidines; Benzylamines; Cross-Over Studies; Drug Combinations; Drug Interactions; Female; Glycine; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Partial Thromboplastin Time; Prodrugs; Pyrroles | 2004 |
No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Anticoagulants; Area Under Curve; Azetidines; Benzylamines; Cross-Over Studies; Digoxin; Double-Blind Method; Drug Interactions; Female; Glycine; Half-Life; Humans; Male; Partial Thromboplastin Time; Prodrugs | 2004 |
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Topics: Adult; Aged; Anticoagulants; Antithrombins; Azetidines; Benzylamines; Chronic Disease; Dalteparin; Glycine; Humans; International Normalized Ratio; Kidney Failure, Chronic; Middle Aged; Renal Dialysis; Uremia | 2005 |
Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarction.
Topics: Aged; Azetidines; Benzylamines; Biomarkers; Blood Coagulation; Dose-Response Relationship, Drug; Female; Fibrin; Glycine; Humans; Male; Myocardial Infarction; Partial Thromboplastin Time; Pharmacokinetics; Thrombin; Time Factors | 2005 |
54 other study(ies) available for melagatran and glycine
Article | Year |
---|---|
The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis.
Topics: Amino Acid Chloromethyl Ketones; Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Carotid Artery Thrombosis; Dose-Response Relationship, Drug; Fibrinolytic Agents; Glycine; Hemodynamics; Heparin; Hirudin Therapy; Hirudins; Kinetics; Male; Oligopeptides; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Piperidines; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Sulfonamides; Thrombin; Thrombin Time | 1997 |
Antithrombotic effect of two low molecular weight thrombin inhibitors and a low-molecular weight heparin in a caval vein thrombosis model in the rat.
Topics: Animals; Azetidines; Benzylamines; Dalteparin; Disease Models, Animal; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Infusions, Intravenous; Injections, Intravenous; Male; Piperidines; Rats; Rats, Wistar; Thrombin; Thrombophlebitis; Vena Cava, Inferior | 1997 |
Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes.
Topics: Administration, Oral; Animals; Azetidines; Benzylamines; Binding, Competitive; Biological Availability; Dogs; Fibrinolytic Agents; Glycine; Hemodynamics; Male; Mice; Mice, Inbred Strains; Molecular Structure; Molecular Weight; Platelet Aggregation Inhibitors; Protease Inhibitors; Rats; Rats, Sprague-Dawley; Serine Proteinase Inhibitors; Thrombin | 1998 |
Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery.
Topics: Administration, Oral; Animals; Antithrombins; Arterial Occlusive Diseases; Azetidines; Benzylamines; Coronary Thrombosis; Dogs; Electric Stimulation; Fibrinogen; Fibrinolytic Agents; Glycine; Microscopy, Electron, Scanning; Partial Thromboplastin Time; Thrombin | 1998 |
Melagatran, a low molecular weight thrombin inhibitor, counteracts endotoxin-induced haemodynamic and renal dysfunctions in the pig.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Creatinine; Diuresis; Drug Evaluation, Preclinical; Endotoxemia; Female; Fibrinolytic Agents; Glycine; Half-Life; Hemodynamics; Kidney; Male; Oxygen Consumption; Partial Thromboplastin Time; Platelet Count; Shock, Septic; Swine; Thrombin | 1998 |
The mechanism of binding of low-molecular-weight active site inhibitors to human alpha-thrombin.
Topics: Antithrombins; Area Under Curve; Arginine; Azetidines; Benzylamines; Binding Sites; Dipeptides; Fluorescence; Glycine; Humans; Kinetics; Molecular Weight; Pipecolic Acids; Piperidines; Spectrometry, Fluorescence; Spectrophotometry; Sulfonamides; Thrombin | 1998 |
Effects of melagatran, an inhibitor of thrombin, on fibrin deposits, haemodynamics, and platelet count in endotoxaemic pigs.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Endotoxemia; Female; Fibrin; Glycine; Hemodynamics; Liver; Male; Platelet Count; Swine; Tumor Necrosis Factor-alpha | 2000 |
Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation; Blood Coagulation Factors; Drug Interactions; Factor VII; Factor VIIa; Glycine; Male; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Thrombosis | 2001 |
Effects of agents, used to treat bleeding disorders, on bleeding time prolonged by a very high dose of a direct thrombin inhibitor in anesthesized rats and rabbits.
Topics: Animals; Anticoagulants; Azetidines; Benzylamines; Bleeding Time; Blood Coagulation Factors; Factor IX; Factor VIIa; Factor VIII; Glycine; Hemorrhage; Humans; Rabbits; Rats; Thrombin; von Willebrand Factor | 2001 |
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects.
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Caco-2 Cells; Glycine; Humans; Intestinal Absorption; Intestinal Mucosa; Male; Prodrugs; Thrombin | 2001 |
[New thrombolytic agents].
Topics: Anticoagulants; Azetidines; Benzylamines; Fibrinolytic Agents; Glycine; Heparin; Humans; Thrombosis; Venous Thrombosis | 2001 |
The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats.
Topics: Administration, Oral; Animals; Antithrombins; Azetidines; Benzylamines; Brain Infarction; Cerebral Cortex; Drug Evaluation, Preclinical; Glycine; Hypertension; Injections, Intravenous; Light; Male; Photochemistry; Piperidines; Rats; Rats, Inbred SHR | 2001 |
Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Glycine; Humans; Indicators and Reagents; Inhibitory Concentration 50; International Normalized Ratio; Prothrombin Time; Sensitivity and Specificity; Thromboplastin | 2001 |
Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry.
Topics: Azetidines; Benzylamines; Chromatography, Liquid; Fibrinolytic Agents; Glycine; Humans; Mass Spectrometry; Reference Standards; Sensitivity and Specificity | 2002 |
Maximized hemostasis.
Topics: Animals; Azetidines; Benzylamines; Carboxypeptidase B2; Fibrinolysis; Glycine; Hemostasis; Humans; Mice; Mice, Knockout; Thrombin; Thrombolytic Therapy; Thromboplastin | 2002 |
Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melagatran).
Topics: Animals; Aorta; Azetidines; Benzylamines; Carboxypeptidase B2; Coronary Circulation; Coronary Thrombosis; Dogs; Enzyme Activation; Enzyme Precursors; Female; Fibrinolytic Agents; Glycine; Male; Models, Animal; Random Allocation; Thrombin; Thrombolytic Therapy; Tissue Plasminogen Activator; Veins | 2002 |
Inhibition of thrombin abrogates the instant blood-mediated inflammatory reaction triggered by isolated human islets: possible application of the thrombin inhibitor melagatran in clinical islet transplantation.
Topics: ABO Blood-Group System; Aged; Aged, 80 and over; Anticoagulants; Azetidines; Benzylamines; Blood Platelets; Cadaver; CD11 Antigens; Female; Fibrin; Glycine; Humans; Immunohistochemistry; Inflammation; Islets of Langerhans; Islets of Langerhans Transplantation; Male; Middle Aged; Neutrophils; Platelet Glycoprotein GPIIb-IIIa Complex; Thrombin; Thrombosis | 2002 |
Monitoring of anticoagulant effects of direct thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation Tests; Drug Monitoring; Glycine; Heparin; Hirudins; Humans; Pipecolic Acids; Recombinant Proteins; Sensitivity and Specificity; Sulfonamides; Thrombin | 2002 |
Comparative antithrombotic potencies of direct thrombin inhibitors and low-molecular-weight heparins in an ex vivo human experimental thrombosis model.
Topics: Antithrombin III; Azetidines; Benzylamines; Fibrin; Fibrinolytic Agents; Glycine; Heparin, Low-Molecular-Weight; Hirudins; Humans; Models, Cardiovascular; Peptide Hydrolases; Platelet Activation; Platelet Factor 4; Thrombin; Thrombosis | 2002 |
Influence of lepirudin, argatroban, and melagatran on prothrombin time and additional effect of oral anticoagulation.
Topics: Administration, Oral; Anticoagulants; Arginine; Azetidines; Benzylamines; Drug Synergism; Glycine; Hirudins; Humans; Phenprocoumon; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Sulfonamides | 2002 |
Effects of ximelagatran, the oral form of melagatran, in the treatment of caval vein thrombosis in conscious rats.
Topics: Administration, Oral; Animals; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hirudins; Male; Prodrugs; Rats; Rats, Sprague-Dawley; Thrombosis; Venae Cavae | 2002 |
Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chromatography, Liquid; Glycine; Humans; Mice; Milk, Human; Rats; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization | 2003 |
Melagatran. Exanta, H 319/68.
Topics: Animals; Azetidines; Benzylamines; Dogs; Fibrinolytic Agents; Glycine; Humans; Mice; Thrombosis | 2002 |
Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors.
Topics: Antithrombins; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Endothelium, Vascular; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Piperidines; Protein C; Thrombin; Thrombomodulin | 2003 |
Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.
Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Dalteparin; Dose-Response Relationship, Drug; Flow Cytometry; Glycine; Heparin; Hirudins; Humans; Male; P-Selectin; Piperidines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIb-IX Complex; Receptor, PAR-1; Receptors, Thrombin; Statistics as Topic; Thrombin | 2003 |
[New anticoagulants -- their clinical significance].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Biological Availability; Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Factor Xa Inhibitors; Fibrinolytic Agents; Fondaparinux; Glycine; Humans; Meta-Analysis as Topic; Polysaccharides; Prodrugs; Risk Factors; Stroke; Thrombosis | 2003 |
[The first oral thrombin inhibitor. Competition to heparins and marcumar?].
Topics: Administration, Oral; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Enoxaparin; Fibrinolytic Agents; Glycine; Humans; Phenprocoumon; Placebos; Prodrugs; Thrombin; Thromboembolism; Thrombosis; Time Factors | 2003 |
Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug.
Topics: Administration, Oral; Amidines; Animals; Azetidines; Benzylamines; Chromatography, High Pressure Liquid; Esters; Glycine; Humans; Hydrolysis; In Vitro Techniques; Kidney; Liver; Microsomes; Mitochondria, Liver; Prodrugs; Swine; Thrombin | 2003 |
Melagatran attenuates fibrin and platelet deposition in a porcine coronary artery over-stretch injury model.
Topics: Angioplasty, Balloon, Coronary; Animals; Azetidines; Benzylamines; Blood Platelets; Coronary Vessels; Dose-Response Relationship, Drug; Female; Fibrin; Fibrinolytic Agents; Glycine; Male; Models, Animal; Platelet Adhesiveness; Radioactive Tracers; Swine; Thrombosis | 2003 |
[Chromogenic substrate as antidote against the thrombin inhibitor Melagatran?].
Topics: Antidotes; Antithrombins; Azetidines; Benzylamines; Chromogenic Compounds; Glycine; Humans; Oligopeptides | 2003 |
Predicting the pharmacology of thrombin inhibitors.
Topics: Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Computer Simulation; Dose-Response Relationship, Drug; Glycine; Hirudins; Humans; Kinetics; Models, Cardiovascular; Oligopeptides; Peptide Fragments; Pipecolic Acids; Recombinant Proteins; Sulfonamides; Thrombin | 2003 |
The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model.
Topics: Animals; Arteries; Azetidines; Benzylamines; Dose-Response Relationship, Drug; Fibrin; Fibrinolytic Agents; Glycine; Hemorrhage; Hirudin Therapy; Hirudins; Male; Rabbits; Risk Assessment; Thrombin; Thrombosis | 2003 |
Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Topics: Animals; Antithrombins; Azetidines; Benzylamines; Chemistry, Pharmaceutical; Constriction, Pathologic; Cyclodextrins; Delayed-Action Preparations; Disease Models, Animal; Drug Evaluation, Preclinical; Endothelium, Vascular; Glycine; Injections, Subcutaneous; Male; Partial Thromboplastin Time; Pharmaceutical Vehicles; Poloxamer; Rats; Rats, Sprague-Dawley; Solutions; Sweden; Thrombin Time; Vena Cava, Inferior; Venous Thrombosis | 2003 |
Improving antithrombotic treatment in patients after myocardial infarction.
Topics: Azetidines; Benzylamines; Clopidogrel; Fibrinolytic Agents; Glycine; Humans; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Ticlopidine; Treatment Outcome; Warfarin | 2003 |
Determination of melagatran in rabbit plasma by high-performance liquid chromatography with automated column switching.
Topics: Animals; Automation; Azetidines; Benzylamines; Calibration; Chromatography, High Pressure Liquid; Glycine; Rabbits; Reproducibility of Results | 2003 |
The influence of direct and antithrombin-dependent thrombin inhibitors on the procoagulant and anticoagulant effects of thrombin.
Topics: Amino Acid Chloromethyl Ketones; Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Coagulants; Coronary Artery Disease; Fibrinopeptide A; Glycine; Hirudins; Humans; Peptide Fragments; Piperidines; Protein C; Thrombin | 2003 |
In vitro effect of melagatran and lepirudin on clot-bound thrombin.
Topics: Anticoagulants; Azetidines; Benzylamines; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Thrombin; Thrombosis | 2003 |
Effects of lepirudin, argatroban and melagatran and additional influence of phenprocoumon on ecarin clotting time.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Blood Coagulation Tests; Fibrinolytic Agents; Glycine; Hirudins; Humans; Kinetics; Outpatients; Phenprocoumon; Recombinant Proteins; Reference Values | 2003 |
Thrombin inhibitor reduces myocardial infarction in apoE-/- x LDLR-/- mice.
Topics: Animals; Apolipoproteins E; Azetidines; Benzylamines; Biomarkers; Coronary Artery Disease; Coronary Thrombosis; Electrocardiography; Glycine; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Myocardial Infarction; Myocardium; Receptors, LDL; Thrombin; Troponin T | 2004 |
Combined effects of melagatran and eptifibatide on platelet aggregation inhibition but not thrombin generation inhibition.
Topics: Azetidines; Benzylamines; Dose-Response Relationship, Drug; Drug Synergism; Eptifibatide; Factor Xa; Glycine; Humans; Peptide Fragments; Peptides; Platelet Aggregation; Platelet Aggregation Inhibitors; Prothrombin; Thrombin; Thromboplastin | 2004 |
Inhibition of thrombin-induced feedback activation of factor V: a potential pathway for inhibition of thrombin generation by melagatran.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Enzyme Activation; Factor V; Glycine; Humans; Prodrugs; Thrombin | 2004 |
The beginning of the end of warfarin?
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Glycine; Humans; Platelet Aggregation Inhibitors; Prodrugs; Thrombin; Warfarin | 2004 |
[Ximelagatran/Melagatran. Perspectives for new oral antithrombin drugs].
Topics: Azetidines; Benzylamines; Glycine; Humans; Prodrugs; Thrombin; Thrombosis | 2004 |
Prevention of venous thromboembolism after orthopedic surgery: the EXPRESS study.
Topics: Anticoagulants; Azetidines; Benzylamines; Clinical Trials as Topic; Dissent and Disputes; Enoxaparin; Glycine; Humans; Orthopedic Procedures; Therapeutic Equivalency; Thromboembolism; Treatment Outcome; Venous Thrombosis | 2004 |
Anticoagulant action of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in umbilical cord and adult plasma: an in vitro examination.
Topics: Adult; Anticoagulants; Antithrombin III; Azetidines; Benzylamines; Blood; Blood Coagulation; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Humans; Infant, Newborn; Peptide Fragments; Peptide Hydrolases; Prothrombin; Thrombin | 2005 |
Drotrecogin alfa activated (recombinant human activated protein C) in combination with heparin or melagatran: effects on prothrombin time and activated partial thromboplastin time.
Topics: Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Drug Evaluation; Drug Therapy, Combination; Fibrinolytic Agents; Glycine; Heparin; Humans; Partial Thromboplastin Time; Peptide Fragments; Protein C; Prothrombin; Prothrombin Time; Recombinant Proteins | 2004 |
Drotrecogin alfa (activated, Xigris) in combination with heparin or melagatran: an in vitro investigation.
Topics: Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Drug Combinations; Glycine; Heparin; Humans; Protein C; Prothrombin Time; Recombinant Proteins | 2004 |
The oral direct thrombin inhibitor, ximelagatran, an alternative for anticoagulant treatment during the puerperium and lactation.
Topics: Administration, Oral; Adult; Anticoagulants; Azetidines; Benzylamines; Breast Feeding; Female; Glycine; Humans; Lactation; Milk, Human; Postpartum Period; Puerperal Disorders; Thrombin; Thromboembolism; Venous Thrombosis | 2005 |
The effects of ximelagatran and warfarin on the prophylaxis of a caval vein thrombosis and bleeding in the anaesthetized rat.
Topics: Animals; Azetidines; Benzylamines; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Glycine; Hemorrhage; Male; Rats; Rats, Sprague-Dawley; Venae Cavae; Venous Thrombosis; Warfarin | 2005 |
Different antithrombotic properties of factor Xa inhibitor and thrombin inhibitor in rat thrombosis models.
Topics: Animals; Azetidines; Benzylamines; Blood Coagulation; Disease Models, Animal; Dose-Response Relationship, Drug; Factor Xa Inhibitors; Fibrinolytic Agents; Glycine; Male; Naphthalenes; Propionates; Rats; Rats, Wistar; Thrombin; Thromboplastin; Thrombosis | 2005 |
Additive effects of anticoagulants: recombinant human activated protein C and heparin or melagatran, in tissue factor-activated umbilical-cord plasma.
Topics: Anticoagulants; Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Blood Coagulation Tests; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Heparin; Humans; Infant, Newborn; Protein C; Prothrombin Time; Recombinant Proteins; Thrombin; Thromboplastin; Umbilical Veins | 2005 |
Comparison of two different ecarin clotting time methods.
Topics: Antithrombins; Azetidines; Benzylamines; Blood Coagulation; Endopeptidases; Glycine; Hirudins; Humans; In Vitro Techniques; Recombinant Proteins; Viper Venoms | 2005 |
Recombinant human activated protein C, heparin and melagatran in umbilical cord versus adult plasma.
Topics: Adult; Anticoagulants; Azetidines; Benzylamines; Blood Coagulation; Dose-Response Relationship, Drug; Fetal Blood; Glycine; Heparin; Humans; Partial Thromboplastin Time; Protein C; Prothrombin Time; Recombinant Proteins | 2005 |
Differences in the clinically effective molar concentrations of four direct thrombin inhibitors explain their variable prothrombin time prolongation.
Topics: Animals; Anticoagulants; Arginine; Azetidines; Benzylamines; Blood Coagulation; Cattle; Dose-Response Relationship, Drug; Factor Xa; Factor Xa Inhibitors; Glycine; Hirudins; Humans; In Vitro Techniques; Partial Thromboplastin Time; Peptide Fragments; Pipecolic Acids; Prothrombin Time; Recombinant Proteins; Species Specificity; Sulfonamides; Thrombin; Thrombin Time; Thromboplastin | 2005 |